India, Aug. 5 -- Lexeo Therapeutics (LXEO) on Wednesday announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM).
PKP2-associated arrhythmogenic cardiomyopathy is a rare inherited heart disease caused by mutations in the PKP2 gene, the most common genetic cause of arrhythmogenic cardiomyopathy. The condition can lead to progressive heart muscle damage, heart rhythm abnormalities, heart failure and sudden cardiac death.
The RMAT designation was granted based on recent interim clinical data from the ongoing HEROIC-PKP2 Phase 1/2 trial evaluating LX2020 in patients with PKP2-ACM.
Acc...